Table 3.
Numbers and infarct size
| |
Condition |
Wild type |
Ob/ob |
DKO |
|||
|---|---|---|---|---|---|---|---|
| Sham | IR | Sham | IR | Sham | IR | ||
|
N experiments (survivors) |
Untreated |
9 (9) |
12 (10) |
7 (7) |
11 (6) |
7 (7) |
9 (7) |
| |
Diet |
|
|
9 (7) |
11 (7) |
9 (7) |
9 (8) |
| |
ACE-I |
6 (6) |
8 (6) |
10 (8) |
10 (8) |
8 (8) |
10 (8) |
|
Area at risk (% of heart) |
Untreated |
0 ± 0 |
14.7 ± 7.5 |
0 ± 0 |
14.0 ± 6.7 |
0 ± 0 |
18.2 ± 7.2 |
| |
Diet |
|
|
0 ± 0 |
17.8 ± 3.4 |
0 ± 0 |
16.4 ± 8.6 |
| |
ACE-I |
0 ± 0 |
17.0 ± 7.1 |
0 ± 0 |
17.1 ± 3.4 |
0 ± 0 |
15.3 ± 5.6 |
|
Infarct size (% of area at risk) |
Untreated |
0 ± 0 |
49.3 ± 6.8b |
0 ± 0 |
72.4 ± 7.2ab |
0 ± 0 |
67.2 ± 6.1ab |
| |
Diet |
|
|
0 ± 0 |
68.4 ± 9.8ab |
0 ± 0 |
70 ± 11.9ab |
| ACE-I | 0 ± 0 | 55.1 ± 5.7b | 0 ± 0 | 69 ± 8.1ab | 0 ± 0 | 68.8 ± 9.9ab | |
ACE-I: angiotensin-converting enzyme inhibition; DKO: double knock-out (ob/ob; LDLR-/-); a” p < 0.05 versus WT same treatment, same condition (sham or IR); “b” p < 0.05 versus sham, same genotype, same treatment.